Immunoexpression of Bcl-x in squamous cell carcinoma and keratoacanthoma: Differences in pattern and correlation with pathobiology

Histopathology

Volumn 55, Issue 3, 2009, Pages 338-345

  Tan, Kong Bing ^a   Lee, Yoke Sun ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Bcl 2; Dermatopathology; Squamoproliferative tumours

Indexed keywords

PROTEIN BCL X;

ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; KERATOACANTHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; BCL-X PROTEIN; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINOCYTES; KERATOACANTHOMA; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 69549097736     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03375.x     Document Type: Article

References (27)

1. L through caspase interaction. Proc. Natl Acad. Sci. USA 1998 95 554 559.
2. Weisfelner ME, Gottlieb AB. The role of apoptosis in human epidermal keratinocytes. J. Drugs Dermatol. 2003 2 385 391.
3. Krajewski S, Krajewska M, Shabaik A et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res. 1994 54 5501 5507.
4. Thamboo TP, Tan LH, Tan SY. Expression of Bcl-x in normal skin and benign cutaneous adnexal tumors. J. Cutan. Pathol. 2006 33 27 32.
5. Wrone-Smith T, Bergstrom J, Quevedo ME, Reddy V, Gutierrez-Steil C, Nickoloff BJ. Differential expression of cell survival and cell cycle regulatory proteins in cutaneous squamoproliferative lesions. J. Dermatol. Sci. 1999 19 53 67.
6. Wrone-Smith T, Johnson T, Nelson B et al. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am. J. Pathol. 1995 146 1079 1088.
7. Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am. J. Pathol. 1997 151 1321 1329.
8. Bongiorno MR, Aricò M. The behaviour of Bcl-2, Bax and Bcl-x in Darier's disease. Br. J. Dermatol. 2002 147 696 700.
9. Beham A, Regauer S, Soyer HP, Beham-Schmid C. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv. Anat. Pathol. 1998 5 269 280.
10. Weedon D. Keratoacanthoma: a personal perspective. Curr. Diagn. Pathol. 2003 9 259 266.
11. Choonhakarn C, Ackerman AB. Keratoacanthomas: a new classification based on morphologic findings and on anatomic site. Dermatopathol. Pract. Concept 2001 7 7 16.
12. Kossard S, Tan KB, Choy C. Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am. J. Dermatopathol. 2008 30 127 134.
13. Gatter KC, Pulford KA, Vanstapel MJ et al. An immunohistological study of benign and malignant skin tumours: epithelial aspects. Histopathology 1984 8 209 227.
14. Slater M, Barden JA. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology 2005 47 170 178.
15. Fernandez-Flores A. Apoptotic markers in the differential diagnosis of keratoacanthoma versus squamous cell carcinoma. Histopathology 2007 50 284 285.
16. Batinac T, Zamolo G, Coklo M, Hadzisejdic I, Stemberger C, Zauhar G. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma. Pathol. Res. Pract. 2006 202 599 607. (Pubitemid 44057766)
17. Tsuji T. Keratoacanthoma and squamous cell carcinoma: study of PCNA and Le(Y) expression. J. Cutan. Pathol. 1997 24 409 415.
18. Batinac T, Zamolo G, Hadzisejdic I, Zauhar G. A comparative study of granzyme B expression in keratoacanthoma and squamous cell carcinoma. J. Dermatol. Sci. 2006 44 109 112. (Pubitemid 44499005)
19. Tran TA, Ross JS, Boehm JR, Carlson JA. Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma. J. Cutan. Pathol. 1999 26 391 397.
20. Blessing K, al Nafussi A, Gordon PM. The regressing keratoacanthoma. Histopathology 1994 24 381 384.
21. Prehn RT. The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma. Cancer Res. 1996 56 937 940.
22. Pena JC, Rudin CM, Thompson CB. A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas. Cancer Res. 1998 58 2111 2116.
23. Pena JC, Fuchs E, Thompson CB. Bcl-x expression influences keratinocyte cell survival but not terminal differentiation. Cell Growth Differ. 1997 8 619 629.
24. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 2004 1644 229 249.
25. Krajewski S, Krajewska M, Ehrmann J et al. Immunohistochemical analysis of Bcl-2, Bcl-x, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am. J. Pathol. 1997 150 805 814.
26. Sorenson CM. Bcl-2 family members and disease. Biochim. Biophys. Acta 2004 1644 169 177.
27. Taylor JK, Zhang QQ, Monia BP, Marcusson EG, Dean NM. Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene 1999 18 4495 4504.